ImmunityBio, Inc. (IBRX)

Triumph Group Revenue

ImmunityBio had revenue of $16.52M in the quarter ending March 31, 2025, with 41,192.50% growth. This brings the company's revenue in the last twelve months to $31.22M, up 10,238.41% year-over-year. In the year 2024, ImmunityBio had annual revenue of $14.75M with 2,270.58% growth.

• Revenue (ttm): $31.22M
• Revenue Growth: +10,238.41%
• P/S Ratio: 57.31
• Revenue / Employee: $45,915
• Employees: 680
• Market Cap: 2.15B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	14.75M	14.12M	2,270.58%
Dec 31, 2023	622.00K	382.00K	159.17%
Dec 31, 2022	240.00K	-694.00K	-74.30%
Dec 31, 2021	934.00K	329.00K	54.38%
Dec 31, 2020	605.00K	-1.60M	-72.52%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.